ArticleTurkish journal of pharmaceutical sciences2025
Preliminary Study on the Development of Orodispersible Film Containing Desloratadine.
Article in Turkish journal of pharmaceutical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Orodispersible films (ODFs) are new-generation dosage forms that increase patient compliance, providing ease of drug administration in many patient groups, such as pediatric, geriatric, and patients with physiological and psychiatric disorders. The aim of this study was to conduct preliminary studies to develop ODF containing the poorly water-soluble and oxidation-sensitive drug desloratadine (DL). Materials and Methods: In this study, the formulation and process parameters, as well as the characterization method were investigated using 20 film formulations manufactured by the solvent casting method. The films were characterized in terms of their appearance, mechanical properties, thickness, disintegration time, and content uniformity. Various strategies have been applied to increase the chemical stability of DL in the formulations and, therefore to choose suitable antioxidants, and morphological and compatibility studies using differential scanning calorimetry were performed. For increasing drug loading, different film compositions were also evaluated. Results: Among the preliminary formulations tested with a casting height of 400 μm, homogeneous, good mechanical properties with tensile strength values between 6.21-10.34 MPa, flexibility, and ODFs with a disintegration time of less than 60s ODFs were developed. By increasing the solubility of DL in the formulation with the selected components, the drug loading capacity was increased to 3% by the desired level. Conclusion: One of the enabling formulations, F20, was particle-free with a suitable thickness uniformity (relative standard deviation =4.6%) and content uniformity (acceptance values =5) films were developed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.